The number of tumor-associated immune cells is correlated with poor prognosis in cancer patients. Reducing these cells in mouse models of breast cancer reduces tumor metastasis, indicating that tumor-immune interactions are critical for cancer progression. In this issue of the Journal of Clinical Investigation, Shelley Earp and colleagues at the University of North Carolina a Chapel Hill demonstrate that removal of the protein MerTK from immune cells decreased tumor growth in mouse models of breast cancer, melanoma, and colon cancer. Loss of MerTK reduced the release of molecules associated with inflammation. These findings suggest that drugs that inhibit MerTK may stimulate anti-tumor responses and could potentially have clinical benefit.
MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis
UNC Lineberger Comp Cancer Center, Chapel Hill, NC, USA
Phone: 919-966-2335; Fax: 919-966-3015; E-mail: email@example.com
View this article at: http://www.jci.org/articles/view/67655?key=e88c1b7bc859757af917
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.